Summary of HR 3955 - RAPID Reserve Act

Bill Overview

The RAPID Reserve Act, formally known as the Rolling Active Pharmaceutical Ingredient and Drug Reserve Act, is a legislative proposal aimed at enhancing the United States' preparedness and response capabilities regarding pharmaceutical supplies. The bill was introduced in the House of Representatives on June 12, 2025, and is currently under consideration by the House Committee on Energy and Commerce.

Purpose and Intent

The primary intent of the RAPID Reserve Act is to establish a strategic reserve of active pharmaceutical ingredients (APIs) and essential drugs. This initiative seeks to ensure that the nation can effectively respond to public health emergencies, such as pandemics or natural disasters, by maintaining a reliable supply of critical medications.

Key Provisions

While the specific provisions of the RAPID Reserve Act have not been detailed in the introduced version, the following key elements are anticipated based on the bill's title and purpose:

• Establishment of a Reserve: The Act is expected to create a federal reserve of APIs and essential drugs that can be quickly mobilized in times of crisis.

• Inventory Management: The bill may outline protocols for the inventory management of these reserves, including regular assessments and updates to ensure the stock remains viable and relevant.

• Collaboration with Manufacturers: The legislation could facilitate partnerships with pharmaceutical manufacturers to ensure a steady supply of necessary ingredients and medications.

• Funding and Resources: The Act may propose funding mechanisms to support the establishment and maintenance of the reserve, although specific dollar amounts have not been disclosed.

Affected Parties

The RAPID Reserve Act would primarily impact:

• Pharmaceutical Manufacturers: Companies involved in the production of APIs and essential drugs may be required to collaborate with the federal government to ensure the reserve is adequately stocked.

• Healthcare Providers: Hospitals and healthcare systems would benefit from the availability of critical medications during emergencies.

• Public Health Agencies: Federal and state health agencies would play a crucial role in managing the reserve and coordinating responses during public health crises.

Legislative Process and Timeline

• Introduced: June 12, 2025
• Referred to Committee: June 12, 2025

The bill is currently in the early stages of the legislative process, having been referred to the House Committee on Energy and Commerce for further review and discussion. The timeline for subsequent actions, including potential hearings or votes, has not yet been established.

Related Legislation

The RAPID Reserve Act has a companion bill, S 2062, which is being considered in the Senate. This parallel effort may facilitate a more comprehensive approach to addressing the nation’s pharmaceutical preparedness.

This summary provides an overview of HR 3955, highlighting its purpose, key provisions, and potential impact on various stakeholders. As the bill progresses through the legislative process, further details and specific provisions may be revealed.